Active, not recruitingPhase 2NCT03331250

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Studying Angiosarcoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Gregory Cote, MD, PhD
Massachusetts General Hospital
Intervention
Eribulin(drug)
Enrollment
13 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (2)

Collaborators

Eisai Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03331250 on ClinicalTrials.gov

Other trials for Angiosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Angiosarcoma →

← Back to all trials